The Canine POMC Gene, Obesity in Labrador Retrievers and Susceptibility to Diabetes Mellitus by Davison, L J et al.
The Canine POMC Gene, Obesity in Labrador Retrievers and
Susceptibil ity to Diabetes Mellitus
L.J. Davison , A. Holder, B. Catchpole, and C.A. O’Callaghan
Background: Diabetes mellitus (DM) in dogs is a common endocrinopathy with a complex genetic architecture. Disease
susceptibility in several breeds is associated with polymorphisms in immune response genes, but in the Labrador retriever
breed, no genetic associations with DM have been identified. A deletion in the pro-opiomelanocortin (POMC) gene in Lab-
rador retrievers is associated with increased appetite and risk of obesity.
Hypothesis/Objectives: To characterize the POMC deletion in Labrador retrievers, to develop a simple genetic test for this
mutation, and to test the hypothesis that the POMC gene deletion is associated with an increased risk of DM in this breed.
Animals: Sixty-one non-diabetic Labrador retrievers aged >6 years and 57 Labrador retrievers with DM.
Methods: Case–control genotyping study to compare the frequency of the POMC deletion in dogs with and without DM.
After polymerase chain reaction (PCR) and sequencing to characterize the mutation, a PCR-based test was developed and
validated using 2 different restriction fragment length polymorphism assays.
Results: A 14-base-pair deletion was confirmed and localized to exon 3 of the canine POMC gene. A PCR-based test for
the deletion was successfully developed. There was no association between the presence of the POMC deletion mutation and
DM in this population of Labrador retriever dogs (P = .31).
Conclusions and Clinical Importance: This study adds to the existing scientific literature indicating that there is little
evidence for a direct link between obesity and DM in dogs.
Key words: Genetics; Endocrinology; Polymerase chain reaction; Pancreas.
Diabetes mellitus (DM) in dogs is a multifactorialdisease, with genetic and environmental compo-
nents thought to contribute to the development of the
condition.1–3 The estimated prevalence of DM in dogs
is 1 in 3004,5 and because most diabetic dogs are insu-
lin-deficient, the disease has been compared to human
type 1 diabetes and latent autoimmune diabetes of the
adult.3 This comparison is supported by the presence of
antibodies to pancreatic autoantigens in a number of
cases6,7 and the lack of evidence of a direct link between
obesity and development of diabetes in dogs, in contrast
to human type 2 diabetes.8
The published genetic studies of DM in dogs are pri-
marily based on a candidate gene approach.9–11 Within
some breeds, certain haplotypes of the canine major his-
tocompatibility complex (encoded by dog leukocyte anti-
gen [DLA] genes) are associated with increased risk of
DM,10 similar to the risk seen with some human leuko-
cyte antigen (HLA) types and type 1 DM. More recently,
using single nucleotide polymorphism (SNP) discovery
and a candidate gene approach, polymorphisms in sev-
eral other immune response and cytokine genes have been
implicated as genetic risk factors in certain breeds.3,11–13
Polymorphisms in genes including those encoding IFN-
gamma, IL-10, IL-12 beta, IL-6, IL-4, PTPN22, and
TNF-alpha have been implicated, with associations
appearing to be most common in moderate risk breeds
including terriers and spaniels. However, the genetic
architecture of DM risk in dogs, like that of human type
1 and type 2 DM, is complex and it is also possible that
specific genetic predispositions differ between breeds.
Many SNPs are associated with protection or susceptibil-
ity in only a single breed, and interestingly, some SNPs
are monomorphic (only 1 allele) within some breeds.11,12
Where DM risk variants are detected, they might only be
important within a single breed (eg, IL10 polymorphisms
in the Cavalier King Charles spaniel12).
A recent candidate gene study14 reported that a
14-base-pair deletion in the canine pro-opiomelanocortin
(POMC) gene is associated with food motivation and
obesity in Labrador retriever dogs. POMC mutations
have also been associated with obesity in humans, with
a subsequent increase in risk of obesity-related diseases
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such as type 2 diabetes.15 Although there is very little
evidence that obesity is a major risk factor for DM in
dogs, obese dogs are hyperinsulinaemic.16 Additionally,
in a recent epidemiological study of DM in first opinion
practice in the UK, being recorded as being overweight
was associated with a diagnosis of DM.4 Furthermore,
research into the links between canine obesity and
nondiestrus diabetes has not been undertaken from a
breed-specific perspective, so this does not rule out an
association between obesity and diabetes in certain
breeds, similar to the association between type 2 DM
and obesity in humans. Therefore, given the absence of
any reported immune response gene associations with
DM in Labrador retrievers, we hypothesized that the
obesity-associated and appetite-associated POMC dele-
tion might also be associated with increased risk of DM
in Labrador retrievers, which may consequently be
more similar to human type 2 than type 1 DM. The
aims of this study were to develop a simple genetic test
for the reported POMC deletion in Labrador retrievers
and to use this test in a population of Labrador retriev-
ers (DM-affected and unaffected) to determine whether
the POMC deletion is present at a higher frequency in
the diabetic population, supporting a potential role for
obesity as a risk factor for DM in this breed.
Materials and Methods
Study Population
Diabetic Dogs. EDTA blood samples from diabetic Labrador
retrievers were retrieved from the UK Canine Diabetes Register
and Archive, at the Royal Veterinary College, University of Lon-
don. The diagnosis was made by primary care veterinary practi-
tioners, based on compatible clinical signs of polydipsia, polyuria,
and weight loss and documented persistent hyperglycemia
(>162 mg/dL), an elevation in serum fructosamine concentration,
or both. Most dogs were receiving insulin treatment at the time of
sampling. Dogs with early-onset diabetes (ie, <1 year of age), con-
current hyperadrenocorticism, and female entire dogs (likely to
have diestrus diabetes), were excluded from the study.
Control Dogs. EDTA blood samples from non-diabetic Labrador
retrievers over 6 years of age were selected from an archive of resid-
ual clinical samples at the Royal Veterinary College, University of
London. Dogs over 6 years of age were selected because this pro-
vided appropriate age-matching for the diabetic samples and limited
the likelihood of these dogs developing diabetes later in life.
All samples used for this study were initially collected for diag-
nostic purposes, and the residual blood volume remaining after
completion of diagnostic testing was stored at 20°C until DNA
extraction. Storage was undertaken with informed owner consent
Table 1. Descriptive statistics of the study population.
Median Age
(Years) [Range]
Male
Neutered (%)
Male
Entire (%)
Female
Neutered (%)
Female
Entire (%)
Sex
Unknown (%)
Total Number
of Dogs
Control population 9 [6–13] 19 (31) 13 (21) 25 (41) 2 (3) 2 (3) 61
Diabetic population 9 [6–13] 18 (32) 14 (25) 25 (43) 0 (0) 0 (0) 57
517 bp
500 bp
C1 C2 C3 C4 C5 C6Marker
Fig 1. Agarose gel electrophoresis after the amplification of a
520-bp region of genomic DNA from 6 Labrador retriever dogs,
using primers designed to flank exon 3 of POMC in the amplicon.
The variability in the size of the amplicons indicates that some
dogs were heterozygous for a 14-base-pair deletion (C3 and C5)
and 1 dog was homozygous for the deletion (C4). This was con-
firmed by sequencing.
Fig 2. Sanger sequencing traces from dogs with homozygous, heterozygous, and wild-type genotypes for the 14-base-pair POMC deletion.
The start point of the deletion is illustrated by a red-dashed line and the end point by a blue-dashed line.
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and with institutional ethical review board approval from the
Royal Veterinary College Ethics and Welfare Committee. DNA
was extracted from EDTA blood using either a standard phenol:
chloroform method or a Qiagen Blood and Tissue DNA extraction
kita and sample quality was evaluated with a Nanodrop analyserb
before polymerase chain reaction (PCR). Where necessary, samples
were re-extracted, diluted, or both to a suitable working concen-
tration (5–20 ng/lL) before use.
Detection and Confirmation of POMC Mutation
Primers were designed to amplify a 560-base-pair (bp) fragment,
containing canine POMC exon 3 (K9POMC-1 sense primer:
50-GCGGCCCTAACCCTCTG-30 and K9POMC-2 antisense primer:
50-GCCACCAGGCCGTACTC-30), with an annealing temperature
of 66°C found to be optimal. Primer 3 software17 was used to
design the primers, and the Canis lupus familiaris POMC gene
transcript (Transcript: POMC-201 ENSCAFT00000006656) was
downloaded from Ensembl at http://www.ensembl.org/Canis_famil
iaris/Info/Index for this purpose. Primers were supplied by IDT
technologiesc , and all PCR reactions were performed on an MJ
PTC-225 thermal cyclerd using Hi-fidelity Hotstart Q5 enzymee .
Amplicons were visualized under UV light with ethidium bro-
mide, after 5% agarose gel electrophoresis at 100 V for 2 hours to
allow optimal resolution of bands. Polymerase chain reaction
products were purified with a Qiagen PCR cleanup kita and sub-
mitted for Sanger sequencingf in a forward and reverse direction
using the same primers as used for PCR. Based on these results, a
further primer set was designed and tested, with the identified dele-
tion located more centrally within the PCR product. This primer
pair was used in all further PCR reactions (K9POMC-3 sense pri-
mer: 50-AAGTACGTCATGGGCCACTT-30 and K9 POMC-4
antisense primer: 50-TTTTGAACAGCGTCACCAGG-30) at an
optimal annealing temperature of 68°C.
Where indicated, restriction fragment length polymorphism
(RFLP) analysis was undertaken on PCR products in 19 NEB
CutSmart buffer and either ApaI enzymee or SacII enzymee for
1 hour at 37°C. The online software NEB Cutter v2.0 at http://nc
2.neb.com/NEBcutter2/ was used to determine suitable enzymes
for this purpose. After digestion, DNA was separated on 4%
A 
B 
Fig 3. (A) illustrates a fragment of the canine POMC gene, demonstrating the delta-exon 3 canine POMC allele (DEL-LAB), missing 14
nucleotides compared with the wild-type allele (WT-LAB). Ensembl transcript POMC-201 ENSCAFT00000006656 (ENSEMBL) in this
region is also shown, with a putative 2 base-pair intron (shown in lower case). The RefSeq (REFSEQ) transcript in this region is also
shown, containing a single putative extra nucleotide “N” (in bold) (The NCBI website notes that the sequence of the model RefSeq tran-
script was modified relative to its source genomic sequence to represent the inferred CDS: inserted 1 base in 1 codon; Derived by auto-
mated computational analysis using gene prediction method: Gnomon). Neither the RefSeq nor the Ensembl canine POMC transcript
shows the G nucleotide (in bold) which was present in both the wild-type and delta-exon 3 Labrador retriever POMC allele in this study.
The deleted nucleotide sequence is AGGGCCCGGCCGCG, which differs by 1 nucleotide from the Ensembl canine reference sequence
(Ensembl transcriptPOMC-201 ENSCAFT00000006656) at position 8 of 14 (C>G) of the 14-bp deleted fragment (shown in white).
(B) illustrates potential impact of the 14-base-pair deletion on the amino acid sequence of wild-type Labrador retriever POMC (WT-LAB)
and delta-exon 3 POMC (DEL-LAB) compared to the published UNIPROT sequence (http://www.uniprot.org/uniprot/E2RQ39.fasta).
The WT sequence differs from the UNIPROT sequence by 1 amino acid, highlighted in black and white. The 14-base-pair delta-exon 3
allele leads to a frameshift mutation with the subsequent amino acid sequence being shown in italics. This frameshift disrupts the 90 amino
acid terminal region of the protein fragment of POMC which is cleaved to form beta lipotropin and subsequently cleaved further to form
beta endorphin and beta melanocyte-stimulating hormone.
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agarose gels containing ethidium bromide for 60 minutes at 120 V
and visualized under UV light. Sequence alignments were per-
formed at http://www.bioinformatics.org/sms2/ and functional
evaluation of the deletion at http://www.uniprot.org/uniprot/
E2RQ39.
Statistical analysis was undertaken by R version 3.2.3.18 A chi-
squared analysis was performed to compare allele frequencies
between diabetic and non-diabetic Labrador retrievers, using a
3 9 2 contingency table with a significant P value set at .05.
Results
A total of 118 Labrador retriever dogs were included
in the study, of which 57 were diabetic and 61 were
non-diabetic. The characteristics of these dogs are
reported in Table 1. The mutation in the canine POMC
gene was reported as a 14-base-pair deletion in exon
3,19 but more precise details of the deletion had not
been published before this study being undertaken. To
confirm this finding, a region of the POMC gene con-
taining exon 3 was amplified (K9POMC-1 and
K9POMC-2 primers) and sequenced in a subset of the
dogs (Fig 1). The predicted amplicon size was 520 bp
(wild-type allele) and 506 bp (POMC deletion allele).
Sanger sequencing was used to confirm the presence
of a 14-base-pair deletion in the canine POMC gene, as
previously reported19 (Fig 2), as this work was under-
taken before the full publication of the mutation
sequence.14 There is some ambiguity in the annotation
of the dog genome sequence containing this deletion,
comparing different databases. Based on the RefSeq
published canine POMC gene (http://www.ncbi.nlm.nih.
gov/nuccore/XM_844370.4), the deletion lies in exon 3.
However, based on the Ensembl transcript (POMC-201
ENSCAFT00000006656), rather than being in exon 3 as
reported in an initial abstract,19 this deletion includes a
small 2-base-pair “intron” (between exons 3 and 4), plus
the first 12 base pairs of exon 4 (Fig 3A). Direct
sequencing of genomic DNA from the Labrador retrie-
ver dogs indicated that the “N” at position 547 of the
RefSeq coding sequence was absent and that there was
an additional G nucleotide base at position 562, imme-
diately preceding the AG, annotated as an intron in the
Ensembl sequence (Fig 3A). Hereafter, the deletion is
referred to as the delta-exon 3 allele.
Once the mutation had been defined in detail, 2 new
primer pairs were designed (K9POMC-3 and
K9POMC-4) flanking the mutation in the centre of the
amplicon, which facilitated RFLP analysis. An ampli-
con length difference as small as 14 base pairs can be
difficult to resolve by agarose gel electrophoresis, partic-
ularly in heterozygotes; therefore, the wild-type and
delta-exon 3 sequences were also examined for differen-
tial restriction enzyme cutting sites. Two restriction
enzymes, ApaI and SacII were tested for this purpose.
ApaI was predicted to cut the wild-type product into 4
fragments (211, 131, 107, and 85 bp), but would cut the
delta-exon 3 allele into only 3 fragments (282, 131 and
107 bp). SacII was predicted to cut the wild-type pro-
duct into 4 fragments (214, 185, 116, and 19 bp), but
would cut the delta-exon 3 allele into only 3 fragments
(385, 116, and 19 bp). Agarose gel electrophoresis con-
firmed these RFLP profiles (Fig 4) with heterozygous
dogs displaying a characteristic triple band, due to
DNA heteroduplex formation. Using standard PCR,
ApaI/SacII digestion, and agarose gel electrophoresis,
11 diabetic and 11 control dogs were screened for the
delta-exon 3 mutation, demonstrating that this
approach allowed the genotypes to be accurately
identified.
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Fig 4. (A) Agarose gel electrophoresis of polymerase chain reac-
tion (PCR) products after amplification of a 534-base-pair frag-
ment of the canine POMC gene in 6 Labrador retriever dogs (C4,
C9, D2, D3, D7, and D10). A combination of low voltage, high
agarose gel content, and long running time allowed separation of
the PCR products from dogs which had homozygous (Ho) or
heterozygous (Het) or wild-type (WT) genotypes with respect to
the 14-base-pair POMC deletion. The triple band in the heterozy-
gotes represents the deleted allele, the wild-type allele, and a
heteroduplex of both alleles. The same PCR products were
digested with ApaI enzyme (B) or SacII enzyme (C) providing con-
firmation of the genotype, as the restriction enzyme digestion sites
are not present in the POMC deletion allele.
4 Davison et al
Using this PCR/RFLP assay, the diabetic and non-
diabetic Labrador retrievers were genotyped for the
delta-exon 3 mutation, the results of which are summa-
rized in Table 2. The minor allele frequency of the
mutation in the total population of all 118 dogs was
0.207. No significant association was identified between
the presence of the POMC delta-exon 3 allele and a
diagnosis of DM in this population of Labrador retriev-
ers.
Discussion
This study aimed to develop a simple genetic test for
the POMC mutation in Labrador retrievers and to test
the hypothesis that the deletion, previously associated
with appetite and obesity in this breed,19 is also associ-
ated with risk of DM. Pro-opiomelanocortin is pro-
duced mainly by the pituitary gland and undergoes a
wide range of post-translational cleavage and modifica-
tion events in a tissue-specific manner20 to generate mel-
anocortins such as adrenocorticotropic hormone
(ACTH), alpha, beta, and gamma melanocyte-stimulat-
ing hormones (MSH). POMC had been selected as a
candidate gene in the canine obesity study15,19 because
of the role of melanocortins in energy metabolism and
appetite.14,15 In veterinary medicine, a polymorphism in
the melanocortin 4 receptor (MC4R) gene has been
associated with DM in overweight cats21 but to date,
no associations between melanocortin/melanocortin
receptor polymorphisms and DM in dogs have been
established.19 Although obesity has not been directly
linked to DM in dogs, it has been shown to cause insu-
lin resistance22 and other metabolic derangements23
which may have a detrimental impact on pancreatic
function or glycemic control, and a recent epidemiologi-
cal study reported that being overweight was associated
with a diagnosis of DM in dogs.4
Using PCR and Sanger sequencing, the 14 bp POMC
deletion was localized to a region of exon 3. This region
of canine POMC exon 3 is not particularly well charac-
terized in the dog genome assembly, with differences
apparent when comparing genome browsers. Direct
sequencing revealed that both RefSeq and Ensembl
sequences (accessed April 25, 2016) were likely incorrect.
The 2-base-pair “intron” in the Ensembl sequence is not
valid as this cannot be spliced out of the primary tran-
script and might, instead, represent an acceptor site for
an alternative mRNA transcript with the donor site after
exon 2. If this were the case, the resulting mRNA species
would encode a protein lacking in c-melanotropin,
ACTH, and a-melanotropin, which seems unlikely. An
additional G nucleotide was identified immediately
upstream of the “AG” splice site, which, when combined
with the AG and translated would result in an encoded
protein more consistent with that found in other species.
Taking this modified sequence as the reference, the 14-
base-pair deletion would lead to loss of 4 amino acids
and a frameshift that would disrupt the coding sequence
(Fig 3B), with a potential impact on expression of beta
lipocortin, beta melanocyte-stimulating hormone, and
beta endorphin.14
The RFLP analysis performed in this study confirmed
the removal of a cleavage sites for both the ApaI
enzyme and the SacII enzyme by the delta-exon 4
POMC deletion and allowed validation of a simple
strategy for POMC genotyping based on PCR and
agarose gel electrophoresis.
The results of genotyping 61 control and 57 diabetic
Labrador retrievers did not demonstrate any association
between the delta-exon 3 POMC deletion and suscepti-
bility to DM. There are several possible reasons for
this, including the presence of phenocopies of disease
within this population, the potentially diverse genetic
backgrounds of non-pedigree dogs identified by their
owners as Labrador retrievers or the possibility that
diabetes risk in Labrador retrievers is driven by a wide
range of genes, each with small effects.
In addition to a genuine lack of association between
POMC and DM in dogs, there are several other poten-
tial reasons for the findings of this study. It is possible
that the study is underpowered, although this appears
unlikely because the genetic architecture of dogs favors
small sample sizes for within-breed genetic studies,24
and the candidate gene study of POMC in which an
association with obesity and appetite was initially dis-
covered involved only 15 obese and 20 lean dogs.19
Unfortunately, data regarding weight and body condi-
tion score of the dogs included in the present analysis
were not available, which is a considerable limitation,
as DM is known to be a complex disease with both
genetic and environmental triggers.1 It is possible for
example that maintenance of a lean bodyweight, even in
an individual prone to obesity because of their delta-
exon 3 POMC genotype, may override any increase in
diabetes risk afforded by the genotype. This could be
explored by a prospective study in which details about
appetite and obesity are collected alongside diabetes
data. Additionally, although control dogs were selected
Table 2. Genotype data for 61 non-diabetic and 57 diabetic Labrador retrievers for the POMC delta-exon 4 muta-
tion and chi-squared analysis of the distribution of alleles across the 2 populations.
POMC Delta-Exon 3 Genotype
Control Dogs Diabetic Dogs
All DogsObserved Expected Chi-Squared Observed Expected Chi-Squared
Wild-type 35 38.25 0.28 39 35.75 0.3 74
Heterozygous deletion 24 20.16 0.73 15 18.84 0.78 39
Homozygous deletion 2 2.58 0.13 3 2.42 0.14 5
Total 61 57 118
The chi-square statistic is 2.36. The P-value is .31. The result is not significant at P < .01.
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to be over 6 years of age, to reduce the likelihood of
dogs in this group developing DM in future, it is still
possible some control dogs might still develop diabetes
in later life, which is another limitation of this study.
Conclusions
This study finds no evidence that a common POMC
14-base-pair deletion in Labrador retrievers, reported to
be associated with obesity and appetite, is associated
with risk of DM in this breed. Splicing events in the
canine POMC gene have not been fully elucidated, but
the deletion is likely to cause a frameshift in the pro-
tein. Restriction fragment length polymorphism-based
genotyping of the mutation can be performed rapidly
and accurately using PCR, ApaI, or SacII enzyme
digestion and agarose gel electrophoresis. This study
adds to the body of evidence that supports a basis for
DM in the Labrador retriever that is not obesity-driven.
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